We will (i) examine relationships between expression window and efficacy across Cas9/Cas12/Cas13 modalities, (ii) identify genome-wide off-target liabilities alongside orthogonal assays, and (iii) discuss controllable, self-limiting, and recallable editor platforms.
First-pass extracted concept
controllable, self-limiting, and recallable editor platforms
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
Current evidence demonstrates promising therapeutic outcomes with manageable safety profiles for sustained CRISPR/Cas expression, but continued monitoring is needed as clinical use broadens.
Quoted textsource-backed
Current evidence demonstrates promising therapeutic outcomes with manageable safety profiles, although there is a need for continued monitoring as CRISPR/Cas therapies are increasingly applied in clinical contexts and therapies are developed for broader clinical applications.
Separating durable edits from persistent nuclease exposure and providing validated control levers establishes a generalizable framework for safer, higher-efficacy CRISPR medicines.
Quoted textsource-backed
By separating durable edits from persistent nuclease exposure, and by providing validated control levers, this work establishes a generalizable framework for safe, higher-efficacy CRISPR medicines.
The field lacks principled guidance on when transient CRISPR editing is sufficient versus when sustained in vivo viral delivery is necessary and how to keep prolonged exposure safe.
Quoted textsource-backed
CRISPR/Cas systems have transformed molecular medicine, yet the field still lacks principled guidance on when transient editing suffices versus when sustained exposure through in vivo viral delivery is necessary and how to keep prolonged exposure safe.